Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Organogenesis Holdings

DB:2PQ
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2PQ
DB
$339M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Organogenesis Holdings has significant price volatility in the past 3 months.
2PQ Share Price and Events
7 Day Returns
7.6%
DB:2PQ
2.2%
DE Biotechs
7.2%
DE Market
1 Year Returns
-61.5%
DB:2PQ
-9%
DE Biotechs
-14.3%
DE Market
2PQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Organogenesis Holdings (2PQ) 7.6% 10.2% -35.9% -61.5% - -
DE Biotechs 2.2% 0.4% -23.6% -9% 16.2% -12.2%
DE Market 7.2% -3.5% -22% -14.3% -19.9% -25.7%
1 Year Return vs Industry and Market
  • 2PQ underperformed the Biotechs industry which returned -9% over the past year.
  • 2PQ underperformed the Market in Germany which returned -14.3% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Organogenesis Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Organogenesis Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Organogenesis Holdings.

DB:2PQ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2PQ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (29.66%))
1.197
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.197 * 5.44%)
6.12%

Discounted Cash Flow Calculation for DB:2PQ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Organogenesis Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:2PQ DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.12%)
2020 -27.00 Analyst x1 -25.44
2021 -13.85 Analyst x2 -12.30
2022 14.00 Analyst x1 11.71
2023 21.10 Est @ 50.75% 16.64
2024 28.58 Est @ 35.41% 21.23
2025 35.63 Est @ 24.67% 24.94
2026 41.74 Est @ 17.15% 27.54
2027 46.70 Est @ 11.89% 29.03
2028 50.53 Est @ 8.2% 29.60
2029 53.37 Est @ 5.63% 29.47
Present value of next 10 years cash flows $152.00
DB:2PQ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $53.37 × (1 + -0.39%) ÷ (6.12% – -0.39%)
$816.59
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $816.59 ÷ (1 + 6.12%)10
$450.84
DB:2PQ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $152.00 + $450.84
$602.84
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $602.84 / 105.36
$5.72
DB:2PQ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2PQ represents 0.87578x of NasdaqCM:ORGO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87578x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 5.72 x 0.87578
€5.01
Value per share (EUR) From above. €5.01
Current discount Discount to share price of €2.82
= -1 x (€2.82 - €5.01) / €5.01
43.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Organogenesis Holdings is available for.
Intrinsic value
44%
Share price is €2.82 vs Future cash flow value of €5.01
Current Discount Checks
For Organogenesis Holdings to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Organogenesis Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Organogenesis Holdings's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Organogenesis Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Organogenesis Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2PQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.44
NasdaqCM:ORGO Share Price ** NasdaqCM (2020-04-08) in USD $3.22
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 42.02x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 17.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Organogenesis Holdings.

DB:2PQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ORGO Share Price ÷ EPS (both in USD)

= 3.22 ÷ -0.44

-7.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Organogenesis Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Organogenesis Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Organogenesis Holdings's expected growth come at a high price?
Raw Data
DB:2PQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
15.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Organogenesis Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Organogenesis Holdings's assets?
Raw Data
DB:2PQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.53
NasdaqCM:ORGO Share Price * NasdaqCM (2020-04-08) in USD $3.22
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.4x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.5x
DB:2PQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ORGO Share Price ÷ Book Value per Share (both in USD)

= 3.22 ÷ 0.53

6.08x

* Primary Listing of Organogenesis Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Organogenesis Holdings is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Organogenesis Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Organogenesis Holdings has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Organogenesis Holdings expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Organogenesis Holdings expected to grow at an attractive rate?
  • Unable to compare Organogenesis Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Organogenesis Holdings's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Organogenesis Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2PQ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2PQ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 15.3%
DB:2PQ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 8.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 37.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2PQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2PQ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 391 1
2023-12-31 367 2
2022-12-31 315 17 -23 4
2021-12-31 279 -7 -36 4
2020-12-31 275 -23 -38 4
2020-04-09
DB:2PQ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 261 -34 -41
2019-09-30 250 -45 -46
2019-06-30 236 -62 -48
2019-03-31 215 -66 -58
2018-12-31 193 -61 -65
2018-09-30 183 -46 -60
2018-06-30 184 -25 -52
2018-03-31 187 -9 -32
2017-12-31 199 -3 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Organogenesis Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Organogenesis Holdings's revenue is expected to grow by 8.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2PQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Organogenesis Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2PQ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 -0.23 -0.20 -0.26 3.00
2021-12-31 -0.35 -0.29 -0.43 4.00
2020-12-31 -0.37 -0.35 -0.38 4.00
2020-04-09
DB:2PQ Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.44
2019-09-30 -0.52
2019-06-30 -0.58
2019-03-31 -0.76
2018-12-31 -0.94
2018-09-30 -0.66
2018-06-30 -0.65
2018-03-31 -0.44
2017-12-31 -0.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Organogenesis Holdings will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Organogenesis Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Organogenesis Holdings has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Organogenesis Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Organogenesis Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Organogenesis Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Organogenesis Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Organogenesis Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Organogenesis Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Organogenesis Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2PQ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 260.98 -41.10 199.69 14.80
2019-09-30 249.94 -45.96 191.73 14.25
2019-06-30 236.44 -47.65 180.84 13.11
2019-03-31 215.04 -58.01 168.44 11.29
2018-12-31 193.45 -64.83 158.30 10.74
2018-09-30 182.99 -60.00 150.30 10.39
2018-06-30 183.68 -52.32 147.48 9.93
2018-03-31 187.08 -31.80 141.80 9.89
2017-12-31 198.51 -8.81 133.93 9.07
2016-12-31 138.73 -16.99 93.03 6.28
2015-12-31 98.98 -24.26 74.22 3.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Organogenesis Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Organogenesis Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Organogenesis Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Organogenesis Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Organogenesis Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Organogenesis Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Organogenesis Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Organogenesis Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Organogenesis Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Organogenesis Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Organogenesis Holdings Company Filings, last reported 3 months ago.

DB:2PQ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 55.58 83.12 60.17
2019-09-30 12.81 83.08 22.97
2019-06-30 23.20 73.15 20.04
2019-03-31 32.56 70.62 30.56
2018-12-31 47.04 41.61 21.29
2018-09-30 -24.23 114.94 25.77
2018-06-30 -57.17 110.86 1.26
2018-03-31 -15.32 106.84 2.31
2017-12-31 -15.32 89.08 2.31
2016-12-31 -15.98 84.49 1.69
2015-12-31
  • Organogenesis Holdings's level of debt (149.5%) compared to net worth is high (greater than 40%).
  • Unable to establish if Organogenesis Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Organogenesis Holdings has sufficient cash runway for 1.5 years based on current free cash flow.
  • Unable to confirm if Organogenesis Holdings has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Organogenesis Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Organogenesis Holdings has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Organogenesis Holdings dividends. Estimated to be 0% next year.
If you bought €2,000 of Organogenesis Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Organogenesis Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Organogenesis Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2PQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2PQ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Organogenesis Holdings has not reported any payouts.
  • Unable to verify if Organogenesis Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Organogenesis Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Organogenesis Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Organogenesis Holdings's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Organogenesis Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Organogenesis Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Organogenesis Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Organogenesis Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gary Gillheeney
COMPENSATION $3,158,313
AGE 64
TENURE AS CEO 6.3 years
CEO Bio

Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Inc., since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organogenesis's Executive Vice President, Chief Operating Officer and Chief Financial Officer from 2003 to 2014 and also Chief Financial Officer from 2002 to 2003. Prior to joining Organogenesis, Mr. Gillheeney held executive positions at Innovative Clinical Solutions, Ltd., a provider of decision support and clinical knowledge solutions to healthcare staff, from 1999 to 2002, as its Chief Operating Officer, Chief Financial Officer, as well as Treasurer and Secretary. Prior to joining Innovative Clinical Solutions, Mr. Gillheeney held positions as Senior Vice President, Chief Financial Officer, Treasurer, and Assistant Secretary at Providence Energy Corporation. Mr. Gillheeney has a B.S. in Accounting from American International College and an M.B.A. from Bryant College.

CEO Compensation
  • Gary's compensation has increased whilst company is loss making.
  • Gary's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Organogenesis Holdings management team in years:

3.3
Average Tenure
57
Average Age
  • The tenure for the Organogenesis Holdings management team is about average.
Management Team

Gary Gillheeney

TITLE
President
COMPENSATION
$3M
AGE
64
TENURE
6.3 yrs

Lori Freedman

TITLE
VP & General Counsel
COMPENSATION
$595K
AGE
52
TENURE
3.3 yrs

Tim Cunningham

TITLE
Chief Financial Officer
AGE
57
TENURE
3.6 yrs

Patrick Bilbo

TITLE
Chief Operating Officer
AGE
57
TENURE
2.6 yrs

Tom Pearl

TITLE
Vice President of Human Resources
TENURE
1.8 yrs

Zorina Pitkin

TITLE
Senior Vice President of Quality Systems
TENURE
12.3 yrs

Brian Grow

TITLE
Chief Commercial Officer
AGE
43
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the Organogenesis Holdings board of directors in years:

1.3
Average Tenure
65
Average Age
  • The average tenure for the Organogenesis Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Alan Ades

TITLE
Chairman of the Board
AGE
80

Gary Gillheeney

TITLE
President
COMPENSATION
$3M
AGE
64
TENURE
1.3 yrs

Arthur Leibowitz

TITLE
Director
COMPENSATION
$85K
AGE
66
TENURE
1.3 yrs

Wayne Mackie

TITLE
Director
COMPENSATION
$84K
AGE
70
TENURE
1.3 yrs

Albert Erani

TITLE
Director
AGE
78
TENURE
1.3 yrs

Glenn Nussdorf

TITLE
Director
AGE
64
TENURE
1.3 yrs

Joshua Tamaroff

TITLE
Director
COMPENSATION
$84K
AGE
33
TENURE
1.3 yrs

Maurice Ades

TITLE
Director
AGE
51
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Mar 20 Buy Avista Capital Holdings, L.P. Company 16. Mar 20 16. Mar 20 37,399 €3.86 €144,301
16. Mar 20 Buy Avista Capital Holdings, L.P. Company 12. Mar 20 16. Mar 20 504,950 €3.86 €1,803,215
27. Nov 19 Buy Avista Capital Holdings, L.P. Company 26. Nov 19 26. Nov 19 6,000,000 €4.54 €27,234,000
16. Sep 19 Buy Michael Katz Individual 13. Sep 19 13. Sep 19 3,603 €5.42 €19,521
16. Sep 19 Buy Wayne Mackie Individual 12. Sep 19 13. Sep 19 4,990 €5.54 €27,604
13. Sep 19 Buy Avista Capital Holdings, L.P. Company 11. Sep 19 11. Sep 19 222,899 €5.68 €1,266,152
13. Sep 19 Buy Avista Capital Holdings, L.P. Company 11. Sep 19 12. Sep 19 638,001 €5.66 €3,414,741
11. Sep 19 Buy Wayne Mackie Individual 09. Sep 19 11. Sep 19 13,010 €5.27 €62,764
10. Sep 19 Buy Avista Capital Holdings, L.P. Company 06. Sep 19 10. Sep 19 537,000 €4.69 €2,518,467
10. Sep 19 Buy Alan Ades Individual 06. Sep 19 06. Sep 19 10,000 €4.55 €45,498
09. Sep 19 Buy Avista Capital Holdings, L.P. Company 06. Sep 19 06. Sep 19 500,000 €4.69 €2,346,032
06. Sep 19 Buy Albert Erani Individual 03. Sep 19 03. Sep 19 100 €3.88 €388
06. Sep 19 Buy Glenn Nussdorf Individual 03. Sep 19 04. Sep 19 100,000 €4.19 €408,259
06. Sep 19 Buy Albert Erani Individual 05. Sep 19 05. Sep 19 5,000 €4.10 €20,513
05. Sep 19 Buy Avista Capital Holdings, L.P. Company 03. Sep 19 05. Sep 19 577,600 €4.43 €2,532,063
06. Sep 19 Buy Arthur Leibowitz Individual 03. Sep 19 03. Sep 19 5,000 €3.83 €19,152
06. Sep 19 Buy Wayne Mackie Individual 03. Sep 19 04. Sep 19 82,000 €4.27 €332,153
06. Sep 19 Buy Michael Katz Individual 04. Sep 19 04. Sep 19 10,000 €4.08 €40,792
X
Management checks
We assess Organogenesis Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Organogenesis Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company’s advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company’s pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Details
Name: Organogenesis Holdings Inc.
2PQ
Exchange: DB
Founded: 1985
$311,973,722
105,356,948
Website: http://organogenesis.com
Address: Organogenesis Holdings Inc.
85 Dan Road,
Canton,
Massachusetts, 02021,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ORGO Class A Common Stock Nasdaq Capital Market US USD 08. Jan 2019
DB 2PQ Class A Common Stock Deutsche Boerse AG DE EUR 08. Jan 2019
Number of employees
Current staff
Staff numbers
835
Organogenesis Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 03:41
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/09
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.